Benserazide, levodopa
Sold as Madopar hbs, Madopar
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Roche Products (Pty) Ltd | Madopar hbs, Madopar | Not stated | 310194, P0150 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Madopar hbs EACH CAPSULE CONTAINS BENSERAZIDE HYDROCHLORIDE 28,5 MG EQUIVALENT TO 25 MG BENSERAZIDE LEVODOPA 100,0 MG | Not listed | 31019431/5.4.1/0194 | Registered | Not determined | None |
| Madopar EACH TABLET CONTAINS BENSERAZIDE HYDROCHLORIDE EQUIVALENT TO 50 mg BENSERAZIDE LEVODOPA 200 mg | Not listed | P0150P/5.4.1/150 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.